Meliodays Medical announces completion of a pre-seed financing of 800,000 euros
Combating menstrual pain through local application of very low doses of painkillers addresses high unmet medical need
Meliodays Medical GmbH, a young pharmaceutical company focusing on the development of a new therapy for the hormone-free and locally acting treatment of menstrual pain, today announces the successful closing of an oversubscribed pre-seed financing round of over 800,000 euros led by capacura GmbH and with participation of FS Life Science Investment GmbH and other early-stage investors and business angels specialized in the healthcare market.
Symbol image
Computer-generated image
Simone Sabbione, co-founder and CEO of Meliodays Medical, said: "We are delighted that we were able to attract such experienced healthcare and impact investors for our first financing round and warmly welcome them to the Meliodays shareholder base. Their investment and the great interest in our significantly oversubscribed pre-seed round show that period pain is now recognized as a serious health burden for large parts of the global population. Now we can finally work on much-needed solutions."
Around 80 percent of menstruating people suffer from period pain, 20-30 percent of which is so severe that it temporarily limits their ability to attend school, work and social activities and often requires the use of pain medication. However, the treatment options currently available, such as hormone therapies or high-dose painkillers, are often associated with systemic side effects.
With the fresh capital, Meliodays Medical will advance the development of MelioOne, a novel, hormone-free, locally acting treatment for menstrual pain, and finalize preparations for preclinical testing of its innovative intra-uterine application. By using a proven polymer technology, a very small amount of painkiller is released specifically in the uterus, effectively combating period pain and avoiding systemic side effects. In the future, Meliodays Medical's innovative technology could also be used in the treatment of endometriosis. The company has already secured the patent rights for MelioOne in over 150 countries.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.